id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2015-E-5107-0006,FDA,FDA-2015-E-5107,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2017-09-20T04:00:00Z,2017,9,2017-09-20T04:00:00Z,,2017-09-20T18:50:36Z,,0,0,0900006482b64a6c
FDA-2015-E-5107-0005,FDA,FDA-2015-E-5107,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-12-13T05:00:00Z,2016,12,2016-12-13T05:00:00Z,,2016-12-13T16:37:30Z,,0,0,0900006482401412
FDA-2015-E-5107-0004,FDA,FDA-2015-E-5107,Determination of Regulatory Review Period for Purposes of Patent Extension; TRESIBA,Notice,Determinations,2016-12-02T05:00:00Z,2016,12,2016-12-02T05:00:00Z,2017-06-01T03:59:59Z,2016-12-02T16:58:01Z,2016-28939,0,0,09000064823d9ecd
FDA-2015-E-5107-0003,FDA,FDA-2015-E-5107,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-01-26T05:00:00Z,2016,1,2016-01-26T05:00:00Z,,2016-01-26T13:57:40Z,,0,0,0900006481e24ed9
FDA-2015-E-5107-0001,FDA,FDA-2015-E-5107,Patent Extension Application from Novo Nordisk A /S,Other,Application,2015-12-31T05:00:00Z,2015,12,2015-12-31T05:00:00Z,,2015-12-31T15:57:59Z,,0,0,0900006481ddf05f
FDA-2015-E-5107-0002,FDA,FDA-2015-E-5107,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2015-12-31T05:00:00Z,2015,12,2015-12-31T05:00:00Z,,2015-12-31T15:58:21Z,,0,0,0900006481ddf0a8